The Role of Anti-Angiogenics in Pre-Treated Metastatic BRAF-Mutant Colorectal Cancer: A Pooled Analysis

Background. FOLFOXIRI plus Bevacizumab is one of the most frequently used first-line treatments for patients with BRAF-mutant colorectal cancer (CRC), while second-line treatment requires extensive further research. In this pooled analysis, we evaluate the impact of anti-angiogenics in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelsomino, Fabio, Casadei-Gardini, Andrea, Rossini, Daniele, Boccaccino, Alessandra, Masi, Gianluca, Cremolini, Chiara, Spallanzani, Andrea, Viola, Massimo Giuseppe, Garajovà, Ingrid, Salati, Massimiliano, Elia, Maria Teresa, Caputo, Francesco, Santini, Chiara, Falcone, Alfredo, Cascinu, Stefano, Tamburini, Emiliano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226019/
https://www.ncbi.nlm.nih.gov/pubmed/32326305
http://dx.doi.org/10.3390/cancers12041022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226019/
https://www.ncbi.nlm.nih.gov/pubmed/32326305
http://dx.doi.org/10.3390/cancers12041022

Ejemplares similares